Search company, investor...

Novalar Pharmaceuticals

novalarpharm.com

Founded Year

2000

Stage

Unattributed VC | Alive

Total Raised

$58.51M

Last Raised

$1M | 13 yrs ago

About Novalar Pharmaceuticals

Novalar Pharmaceuticals develops a drug agent that is designed to reverse the effects of local anesthesia applied in dental procedures, thereby allowing patients to return to their daily activities without the speech impediments, lip biting, and difficulty in eating that can be caused by unintended soft-tissue anesthesia.

Headquarters Location

12555 High Bluff Drive Suite 300

San Diego, California, 92130,

United States

858-436-1100

Missing: Novalar Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Novalar Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Novalar Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Novalar Pharmaceuticals is included in 2 Expert Collections, including Dental Health.

D

Dental Health

959 items

Companies delivering dental care products and services. Excludes practice networks.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Novalar Pharmaceuticals Patents

Novalar Pharmaceuticals has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/18/2005

8/18/2009

Beta blockers, General anesthetics, Imidazolines, Phenols, Anesthesia

Grant

Application Date

3/18/2005

Grant Date

8/18/2009

Title

Related Topics

Beta blockers, General anesthetics, Imidazolines, Phenols, Anesthesia

Status

Grant

Latest Novalar Pharmaceuticals News

Novalar Pharmaceuticals Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Nov 29, 2016

Novalar Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 23:14 EST 28 Nov 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Novalar Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Novalar Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Novalar Pharmaceuticals, Inc. since January 2007. Key Findings Provides intelligence on Novalar Pharmaceuticals, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Novalar Pharmaceuticals, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Novalar Pharmaceuticals, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Novalar Pharmaceuticals, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Novalar Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Novalar Pharmaceuticals founded?

    Novalar Pharmaceuticals was founded in 2000.

  • Where is Novalar Pharmaceuticals's headquarters?

    Novalar Pharmaceuticals's headquarters is located at 12555 High Bluff Drive, San Diego.

  • What is Novalar Pharmaceuticals's latest funding round?

    Novalar Pharmaceuticals's latest funding round is Unattributed VC.

  • How much did Novalar Pharmaceuticals raise?

    Novalar Pharmaceuticals raised a total of $58.51M.

  • Who are the investors of Novalar Pharmaceuticals?

    Investors of Novalar Pharmaceuticals include Boston Millennia Partners, SR One, Montreux Equity Partners, Domain Associates, Endeavour Vision and 5 more.

  • Who are Novalar Pharmaceuticals's competitors?

    Competitors of Novalar Pharmaceuticals include Kiadis Pharma, Xhale, Actinobac Biomed, SpiroGen, AI2 and 12 more.

Compare Novalar Pharmaceuticals to Competitors

P
Psimei Pharmaceutical

Psimei Pharmaceuticals is developing boron-based drugs for applications in Photon Activation Therapy (PAT). This involves the use of standard radiotherapy to activate boron-based compounds which selectively target solid tumours. This results in an amplification of the therapeutic effect of conventional radiotherapy. Pre-clinical data for Psimei's lead product, PP200PAT, has demonstrated 90% true cure rates at 6 months in tumour models compared with 30% for conventional radiotherapy alone. It also enabled much shorter treatment regimes - days as opposed to weeks. This drug is being prepared for clinical development.

E
Eagle Vision Pharmaceutical

Eagle Vision Pharmaceutical Corporation - The Eagle Vision SeeMoreTM imaging agent is a of its kind to harness the power of MRI to provide results in three critical areas: cardiac perfusion, cardiac function and cardiac vessel status, which today require multiple tests that cost thousands of dollars. The metabolic imaging agent based on manganese uptake is being tested in phase II clinical studies. In addition, the company has preclinical data for its use in solid tumor imaging in breast cancer, as well as hepatic disease.

T
ThyroChek

ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.

O
Onyvax

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

Q
Quark Pharmaceuticals

Quark Pharmaceuticals is a development-stage pharmaceutical company discovering and developing RNA interference (RNAi)-based therapeutics.

M
Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.